Hoth Therapeutics (NASDAQ:HOTH) Rating Reiterated by HC Wainwright

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 351.21% from the stock’s previous close.

A number of other brokerages also recently commented on HOTH. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Benchmark restated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Stock Up 8.1 %

NASDAQ HOTH opened at $0.89 on Wednesday. The company has a fifty day moving average of $0.83 and a two-hundred day moving average of $0.98. The firm has a market capitalization of $4.75 million, a price-to-earnings ratio of -0.46 and a beta of 0.84. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.15. Equities research analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.